Irlanda - inglés - HPRA (Health Products Regulatory Authority)

3m health care limited - pirbuterol hydrochloride - tablets - 15 milligram

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

3m health care limited - pirbuterol -

Estados Unidos - inglés - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 0.31 mg in 3 ml - levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. risk summary there are no adequate and well-controlled studies of levalbuterol inhalation solution in pregnant women. there are clinical considerations with the use of levalbuterol inhalation solution in pregnant women [see clinical considerations]. following oral administration of levelbuterol hcl to pregnant rabbits, there was no evidence of teratogenicity at doses up to 25 mg/kg/day [approximately 108 times the maximum recommended human daily inhalation dose (mrhdid) of levalbuterol hcl for adults on a mg/m2 basis]; however, racemic a

Estados Unidos - inglés - NLM (National Library of Medicine)

prasco laboratories - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 0.31 mg in 3 ml - levalbuterol hcl inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol hcl inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medication, including levalbuterol hcl inhalation solution, during pregnancy. to enroll in mothertobaby pregnancy studies' asthma & pregnancy study or for more information about the registry, call 1-877-311-8972 or visit www.mothertobaby.org/ongoing-study/asthma. risk summary there are no adequate and well-controlled studies of levalbuterol hcl inhalation solution in pregnant women. there are clinical con

Estados Unidos - inglés - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - levalbuterol hydrochloride (unii: wdq1526qjm) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 1.25 mg in 0.5 ml - levalbuterol inhalation solution (concentrate) is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. levalbuterol inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see warnings and precautions (5.6) ]. risk summary there are no adequate and well-controlled studies of levalbuterol inhalation solution concentrate in pregnant women. there are clinical considerations with the use of levalbuterol inhalation solution concentrate in pregnant women [see clinical considerations]. following oral administration of levalbuterol hcl to pregnant rabbits, there was no evidence of teratogenicity at doses up to 25 mg/kg/day [approximately 108 times the maximum recommended human daily inhalation dose (mrhdid) of levalbuterol hcl for adults

Estados Unidos - inglés - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levalbuterol tartrate (unii: ads4i3e22m) (levalbuterol - unii:edn2nbh5ss) - levalbuterol 45 ug - levalbuterol tartrate hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease. levalbuterol tartrate hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol, or any other component of levalbuterol tartrate hfa inhalation aerosol. reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. teratogenic effects: pregnancy category c there are no adequate and well-controlled studies of levalbuterol tartrate hfa inhalation aerosol in pregnant women. because animal reproduction studies are not always predictive of human response, levalbuterol tartrate hfa inhalation aerosol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. rare instances of congenital anomalies, including cleft palate and limb defects, were reported in

Estados Unidos - inglés - NLM (National Library of Medicine)

actavis pharma, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 0.63 mg in 3 ml - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease). albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components. read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication, as you may want to read them again. albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about albuterol sulfate inhalation solution and the condition for which it has been prescribed. contact them if you have additional questions. storing your medicine store albuterol sulfate inhalation solution between 20° and 25° c (68° and 77° f). [see usp controlled room temperature]. vials should be protected from light before use, therefore, keep unused vials in the foil pouch. d

Estados Unidos - inglés - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 0.75 mg in 3 ml - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease). albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components.

Estados Unidos - inglés - NLM (National Library of Medicine)

nephron pharmaceuticals corporation - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 1.25 mg in 3 ml - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease). albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components.

Estados Unidos - inglés - NLM (National Library of Medicine)

physicians total care, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate 1.5 mg in 3 ml - albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease). albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components.